Condition: Myelosuppression · Thoracic Neoplasms · Chemoradiotherapy · Sponsor: Affiliated Hospital of Nantong University
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
This description comes directly from the study's public registry record.
Zhiming CHEN · 86+15851396885 · chenzhiming@ntu.edu.cn
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Nantong University | Nantong, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07205536